Refractory Atypical Teratoid/Rhabdoid Tumor
specificAn atypical teratoid/rhabdoid tumor that does not respond to treatment.
13
Centers
13
Active Trials
—
Cancer Funding
Top Centers for Refractory Atypical Teratoid/Rhabdoid Tumor(13)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 53.8 |
| 2 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 53.8 |
| 3 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive Active Research Program | 53.8 |
| 4 | Vanderbilt-Ingram Cancer CenterNashville, TN NCI Comprehensive Active Research Program | 53.8 |
| 5 | Herbert Irving Comprehensive Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 53.8 |
| 6 | Duke Cancer InstituteDurham, NC NCI Comprehensive Active Research Program | 53.8 |
| 7 | NCI Comprehensive Active Research Program | 53.8 |
| 8 | Masonic Cancer CenterMinneapolis, MN NCI Comprehensive Active Research Program | 53.8 |
| 9 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 53.8 |
| 10 | Medical College of Wisconsin Cancer CenterMilwaukee, WI Active Research Program | 53.8 |
| 11 | University of Illinois Cancer CenterChicago, IL Active Research Program | 53.8 |
| 12 | Boston University Cancer CenterBoston, MA Active Research Program | 53.8 |
| 13 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 53.8 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →